Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
But some other N-containing compounds like porphyrins and chlorophylls strongly bound Cu, Fe, Co, and Ni by forming complexes
Thymosin 4 enhances the healing of medial collateral ligament injury in rats
( G ) Immunoblot analysis of HJURP, KNL2, and CENP-C using anti-HJURP, anti-KNL2, and anti-CENP-C antibodies, respectively, in AID-based CENP-C knockout cells with Tet-based HJURP-cKO background expressing Halo-HJURP (WT) or Halo-HJURP 8K (8K) in the presence (+) or absence () of IAA (5 h)
The Role of Hypomagnesemia in Cardiac Arrhythmias
